Literature DB >> 25443268

Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study.

Valeria Panebianco1, Flavio Barchetti2, Alessandro Sciarra3, Antonio Ciardi2, Elena Lucia Indino2, Rocco Papalia4, Michele Gallucci4, Vincenzo Tombolini2, Vincenzo Gentile3, Carlo Catalano2.   

Abstract

OBJECTIVES: To assess whether the proportion of men with clinically significant prostate cancer (PCa) is higher among men randomized to multiparametric magnetic resonance imaging (mp-MRI)/biopsy vs. those randomized to transrectal ultrasound (TRUS)-guided biopsy.
METHODS: In total, 1,140 patients with symptoms highly suggestive of PCa were enrolled and divided in 2 groups of 570 patients to follow 2 different diagnostic algorithms. Group A underwent a TRUS-guided random biopsy. Group B underwent an mp-MRI and a TRUS-guided targeted+random biopsy. The accuracy of mp-MRI in the diagnosis of PCa was calculated using prostatectomy as the standard of reference.
RESULTS: In group A, PCa was detected in 215 patients. The remaining 355 patients underwent an mp-MRI: the findings were positive in 208 and unremarkable in 147 patients. After the second random+targeted biopsy, PCa was detected in 186 of the 208 patients. In group B, 440 patients had positive findings on mp-MRI, and PCa was detected in 417 at first biopsy; 130 group B patients had unremarkable findings on both mp-MRI and biopsy. In the 130 group B patients with unremarkable findings on mp-MRI and biopsy, a PCa Gleason score of 6 or precancerous lesions were detected after saturation biopsy. mp-MRI showed an accuracy of 97% for the diagnosis of PCa.
CONCLUSIONS: The proportion of men with clinically significant PCa is higher among those randomized to mp-MRI/biopsy vs. those randomized to TRUS-guided biopsy; moreover, mp-MRI is a very reliable tool to identify patients to schedule in active surveillance.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biopsy; Magnetic resonance imaging; Prostate cancer; Prostate-specific antigen; Ultrasonography

Mesh:

Substances:

Year:  2014        PMID: 25443268     DOI: 10.1016/j.urolonc.2014.09.013

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  64 in total

1.  Intravoxel Incoherent Motion (IVIM) Diffusion Weighted Imaging (DWI) in the Periferic Prostate Cancer Detection and Stratification.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Silvia Panella; Anna Maria Ierardi; Giovanni Guido Pompili; Giuseppe Franceschelli; Salvatore Alessio Angileri; Alberto Magenta Biasina; Gianpaolo Carrafiello
Journal:  Med Oncol       Date:  2017-01-31       Impact factor: 3.064

2.  Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate.

Authors:  Aritrick Chatterjee; Sevil Tokdemir; Alexander J Gallan; Ambereen Yousuf; Tatjana Antic; Gregory S Karczmar; Aytekin Oto
Journal:  AJR Am J Roentgenol       Date:  2018-11-07       Impact factor: 3.959

3.  [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].

Authors:  C Kesch; J P Radtke; F Distler; S Boxler; T Klein; C Hüttenbrink; K Hees; W Roth; M Roethke; H P Schlemmer; M Hohenfellner; B A Hadaschik
Journal:  Urologe A       Date:  2016-08       Impact factor: 0.639

Review 4.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

5.  The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.

Authors:  Pedro Recabal; Melissa Assel; Daniel D Sjoberg; Daniel Lee; Vincent P Laudone; Karim Touijer; James A Eastham; Hebert A Vargas; Jonathan Coleman; Behfar Ehdaie
Journal:  J Urol       Date:  2016-02-23       Impact factor: 7.450

Review 6.  Prostate MR Imaging for Posttreatment Evaluation and Recurrence.

Authors:  Sonia Gaur; Baris Turkbey
Journal:  Radiol Clin North Am       Date:  2017-11-27       Impact factor: 2.303

7.  Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis.

Authors:  Michael Nguyentat; Alexander Ushinsky; Alessandra Miranda-Aguirre; Edward Uchio; Chandana Lall; Layla Shirkhoda; Thomas Lee; Christopher Green; Roozbeh Houshyar
Journal:  Curr Probl Diagn Radiol       Date:  2017-10-12

8.  Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.

Authors:  Frank-Jan H Drost; Daniël F Osses; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Monique J Roobol; Ivo G Schoots
Journal:  Cochrane Database Syst Rev       Date:  2019-04-25

9.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

Review 10.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.